Obalon Therapeutics Inc represents a values-driven corporate philosophy centered on innovation, patient care, and transformative solutions. As a medical technology company, Obalon is dedicated to providing safe and effective weight loss solutions. The company's commitment to excellence is evident in its FDA-approved, swallowable, and non-surgical weight loss system. Obalon's mission is to address the global obesity epidemic by empowering individuals to achieve their weight loss goals. Through their cutting-edge products and a patient-centric approach, Obalon Therapeutics Inc aims to transform lives and improve overall health and well-being.

Obalon Therapeutics Inc is primarily present in the United States.

Obalon Therapeutics Inc has achieved various significant milestones. The company developed and gained FDA approval for the Obalon Balloon System, a non-surgical weight loss treatment. It also received CE Mark approval for commercialization in Europe. In addition, Obalon entered into collaboration agreements with major pharmaceutical companies and expanded its global footprint. The company successfully conducted clinical studies demonstrating the efficacy and safety of the Obalon Balloon System. Moreover, Obalon Therapeutics Inc has been recognized for its innovations and received prestigious awards. These achievements highlight the company's commitment to revolutionizing weight loss solutions and improving patient outcomes.

Obalon Therapeutics Inc, a renowned medical technology company, specializes in developing and commercializing innovative tools for weight loss. Founded in 2008, Obalon has successfully introduced the Obalon Balloon System, a non-surgical, FDA-approved device designed to assist patients in achieving their weight loss goals. The company is committed to providing effective, safe, and minimally invasive solutions to combat obesity and improve overall patient health. Obalon Therapeutics Inc has grown its presence in the market through extensive research and development, strategic partnerships, and a passion for transforming the lives of individuals struggling with weight management. With its cutting-edge technology and dedication to patient care, Obalon continues to revolutionize the field of weight loss intervention.

The main competitors of Obalon Therapeutics Inc in the market include other companies operating in the medical technology sector, specifically those focused on weight loss solutions. Some notable competitors in this space include EnteroMedics Inc, ReShape Lifesciences Inc, and Medtronic Plc. These companies offer similar non-surgical weight loss treatments and devices, posing potential competition for Obalon Therapeutics Inc. However, it is important to note that market dynamics and competition can change over time, and it is recommended to gather updated information to accurately assess competitors in the market.

Obalon Therapeutics Inc is primarily active in the healthcare and medical devices industry.

Obalon Therapeutics Inc. is a medical technology company that focuses on developing and commercializing innovative products for weight loss. Their business model revolves around the sale of the Obalon Balloon System, a non-surgical, ingestible device designed to help individuals achieve weight loss goals. This system consists of a series of lightweight balloons that are swallowed and then inflated in the stomach to create a feeling of fullness, thereby reducing calorie intake. Obalon Therapeutics Inc. combines this device with a comprehensive weight management program to provide individuals with a safe and effective solution for long-term weight loss.

P/E-lukua ei voida tällä hetkellä laskea kohteelle Obalon Therapeutics.

KUV:tä ei voida tällä hetkellä laskea Obalon Therapeutics osalta.

AlleAktien Laatuscore Obalon Therapeutics on 1/10.

Liikevaihtoa ei voida tällä hetkellä laskea yritykselle Obalon Therapeutics.

Voitto ei voida tällä hetkellä laskea yritykselle Obalon Therapeutics.

Obalon Therapeutics Inc is a medical technology company that specializes in the development and marketing of innovative weight loss therapy options. The company focuses on non-invasive, minimally invasive, and controlled weight loss and produces and distributes various products for this purpose. The main product of Obalon Therapeutics is the Obalon Balloon System, a non-invasive weight loss system based on the idea that a balloon in the stomach can effectively induce fullness and satiety, reducing the desire for food. The balloon is swallowed under the supervision of medical professionals and then filled with gas to create enough space in the stomach. The balloon in the stomach creates a feeling of fullness, leading the patient to eat less. Obalon Therapeutics' products are primarily aimed at overweight people who have been unsuccessful in reducing their weight through diets and exercise. But also, individuals who are physically unable to perform physically demanding activities such as jogging, training, or other exercises find a meaningful solution in the use of the balloon system. Treatment with the Obalon Balloon System typically lasts three to six months, and the company recommends accompanying diet and exercise therapy to ensure long-term weight loss. Obalon Therapeutics also offers training and education for medical professionals to integrate the balloon system into their practice and pass it on to their patients. In addition, the company provides a program for review and verification to ensure that the prescription and use of the balloon system comply with current regulations. Obalon Therapeutics' business model is designed to benefit both the patient and the medical professionals. Patients receive a non-invasive, easy-to-use weight loss system that is performed under direct medical supervision. At the same time, medical professionals have an innovative and effective tool at hand to help their patients with weight loss while increasing their practice revenue. The company also relies on a comprehensive marketing strategy to promote its products. This includes digital advertising such as online advertising, email campaigns, and social media marketing, as well as participation in medical conferences and events. Overall, Obalon Therapeutics' business model is focused on providing an effective weight loss solution that supports patients in achieving their goals while also providing doctors and medical professionals with an effective tool. With a wide range of products and services tailored to the needs of a growing market, the company has the potential to strengthen its growth and presence in the field of medical weight control.

Obalon Therapeutics maksaa osinkoa 0 USD, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Obalon Therapeutics:lle tai yhtiö ei maksa osinkoa.

Obalon Therapeutics:n ISIN on US67424L2097.

Obalon Therapeutics:n WKN on A2PPB1.

Obalon Therapeutics:n tunnus on OBLN.

Viimeisen 12 kuukauden aikana Obalon Therapeutics maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Obalon Therapeutics maksanee ennusteiden mukaan 0 USD osingon.

Obalon Therapeutics:n tämänhetkinen osinkotuotto on .

Obalon Therapeutics maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Obalon Therapeutics maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 USD suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Obalon Therapeutics kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Obalon Therapeutics osingon 20.11.2024, jonka suuruus on 0 USD, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 20.11.2024.

Viimeisin osinko maksettiin 20.11.2024.

Vuonna 2023 Obalon Therapeutics maksoi 0 USD osinkoina.

Obalon Therapeutics:n osingot maksetaan USDssa.